Stock Price & Analysis

Based on the provided data and current market conditions, here's my analysis for BAX stock:

Technical Analysis

The stock is currently trading at $30.82, showing a modest gain of 0.65% in the last trading session. The stock has been in a downtrend over the past year but has shown some signs of stabilization in early 2025.

Fundamental Analysis

Key metrics for BAX:

• P/S Ratio: 1.77
• EV/EBITDA: 13.48
• P/B Ratio: 4.41
• Dividend Yield: 2.26%

Recent Developments

1. Kidney Care Unit Sale: Baxter is in discussions with Carlyle Group to sell its kidney care business (Vantive) for over $4 billion. This strategic move aims to:

• Create a more focused company
• Improve operational efficiency
• Reduce debt levels
• Enable better capital allocation

2. Financial Performance:

• Revenue: $14.5 billion (2022)
• Net Income: -$2.43 billion (2022)
• Gross Margin: 35.1%
• Current Ratio: 1.69

Analyst Sentiment

According to recent analyst coverage:

• Consensus: Hold
• Mean Price Target: $37.12 (17.3% upside potential)
• Street High Target: $42 (32.7% upside)
• Coverage: 13 analysts (2 Strong Buy, 10 Hold, 1 Moderate Sell)

Recommendation

HOLD - While the company's strategic restructuring through the Vantive sale could improve its financial position, several factors suggest caution:

1. The stock is showing early signs of stabilization but remains in a broader downtrend
2. Fundamental metrics indicate fair valuation relative to peers
3. The pending Vantive sale could create near-term volatility
4. Analyst consensus remains neutral

Wait for more clarity on:

• Completion of the Vantive sale
• Improved operational metrics
• Technical confirmation of trend reversal

Based on the available data and market analysis, here is the price prediction for BAX stock in 2025:

Technical Analysis

Price Target Analysis The stock is expected to trade in the range of $35-40 by end of 2025, representing a potential upside of 15-30% from current levels. This projection is supported by:

1. Wall Street analysts maintain a "Hold" rating with a mean price target of $37.12, suggesting a 17.3% upside potential, with the most bullish target at $42 indicating 32.7% upside.

2. The company's strategic restructuring through discontinuing Kidney Care operations and focus on core medical products business is expected to improve profitability margins in 2025.

Key Drivers The price movement will be primarily driven by:

• Continued demand recovery in medical products segment
• Margin improvement from restructuring initiatives
• Healthcare sector performance in 2025 amid expected economic conditions

The stock shows potential for moderate upside in 2025, though execution risks around restructuring and broader market conditions could impact the trajectory. The most likely scenario points to the stock reaching $37-38 range by year-end 2025.

The S1 support level for BAX Stock is $30.16 ,The R1 resistant level for BAX Stock is $33.31.

As of the end of day on 2025-02-21, the price of BAX Stock was $34.

The target price for BAX Stock according to analyst rating is 36.75, with the highest price target at 42.00 and the lowest at 30.00. Analysts have a Hold rating on BAX Stock overall.

The market cap of BAX is $17.3B.

Based on the provided data and recent market analysis, BAX appears fairly valued to slightly undervalued. The stock's EV/EBITDA ratio has decreased from 13.48 in 2022 to 10.58 in 2023, indicating improved valuation metrics. The P/S ratio of 1.32 and P/B ratio of 2.34 are both below historical averages, suggesting reasonable valuation levels.

The company's financial performance shows mixed signals with revenue growing modestly from $14.51B to $14.81B in 2023, while transitioning from a net loss to positive earnings. The gross margin improved slightly to 35.89% in 2023.

Technical indicators show the stock is currently in a neutral to slightly bearish position, with RSI-14 at 46.41 indicating neither overbought nor oversold conditions. The stock is trading below both its 200-day SMA ($34.19) and 60-day SMA ($31.14).

Wall Street sentiment remains cautious with a consensus "Hold" rating from 13 analysts, though the mean price target of $37.12 suggests a 17.3% upside potential from current levels.

The debt level remains a concern with a debt-to-equity ratio of 162.94%, though this has improved from 282.21% in 2022.

Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies and precision positioning devices. Its Pharmaceuticals segment includes specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding. Its Kidney Care segment includes chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies (CRRT) and other organ support therapies.

Based on the provided data and recent market developments, here's a price prediction for BAX stock in 2030:

BAX stock is projected to reach $45-50 by 2030, representing a 45-62% increase from current levels of $30.82, driven by the company's strategic focus on core medical technology segments and operational efficiency improvements. The company's strong market position in critical care and hospital products, combined with its recent restructuring efforts to discontinue Kidney Care operations, positions it for sustainable long-term growth.

The conservative growth projection factors in the company's current challenges but recognizes its fundamental strengths in healthcare technology and global presence in over 100 countries. Recent analyst consensus maintains a "Hold" rating with a mean price target of $37.12 for the near term, suggesting steady but measured growth potential.

BAX has a total of 60000 employees.